National Psoriasis Foundation adds six to Medical Board

The National Psoriasis Foundation named six new members to its Medical Board on Aug. 10, expanding a group that helps guide clinical direction, treatment guidance and provider education. The appointments are meant to strengthen the group’s work on psoriatic disease research, care and education.

Why it matters: - The new appointments add dermatology, rheumatology, clinical care and research expertise to a board that helps shape how psoriatic disease is studied and treated. - The Medical Board’s work can influence provider education, treatment access and patient care for people living with psoriasis and psoriatic arthritis. - NPF says the board supports its broader mission to cure psoriatic disease and improve outcomes for more than 8 million people in the U.S. affected by the condition.

What happened: - The National Psoriasis Foundation announced six new Medical Board members on Aug. 10, 2026. - The appointees are Robert Bissonnette, M.D., FRCPC; Wendy Cantrell, DNP, CRNP; Stephen Fakharzadeh, M.D., Ph.D.; Joseph Gorelick, MSN, FNP-BC; Alice Gottlieb, M.D., Ph.D.; and Wilson Liao, M.D. - NPF said the additions reflect a shared commitment to advancing its mission to improve the lives of people affected by psoriatic disease. - The Medical Board now includes more than 30 leading experts and is chaired by Andrew Blauvelt, M.D., M.B.A.

The details: - The Medical Board provides clinical direction, treatment guidance and provider education oversight to NPF and its executive leaders. - Board members contribute to NPF’s continuing medical education work through program development, presentations and educational activities for healthcare providers and patients. - The board also contributes to the NPF Expert Manuscript program. - That program brings together multidisciplinary experts to produce publications that can expand understanding of psoriatic disease and affect treatment access, clinical practice and patient care. - NPF recently published a primer on GLP-1 receptor agonist use in patients with psoriatic disease. - That primer ranks among the top 5% of research outputs tracked by Altmetric. - NPF and the International Psoriasis Council also published a joint statement on routine testing for latent tuberculosis. - NPF said that publication has already had a measurable impact on therapeutic management of psoriatic disease. - Leah M. Howard, J.D., NPF president and CEO, said the new members will add thought leadership and clinical expertise to help advance the vision of a world without psoriasis and psoriatic arthritis. - Guy Eakin, Ph.D., NPF chief scientific and medical officer, said the board helps shape the clinical and research landscape and supports patient-centered care.

Between the lines: - The appointments show NPF is leaning on a broader mix of specialties as psoriatic disease care becomes more interdisciplinary. - NPF is also signaling that its advisory boards are not just honorary groups; they are tied to education, publications and practice-changing guidance. - The emphasis on research outputs and joint statements suggests NPF is trying to move from advocacy into measurable clinical influence.

What's next: - NPF will continue using the Medical Board to guide education, research publications and clinical recommendations. - The full list of Medical Board members and other advisory committees is available at psoriasis.org/medical-board. - NPF will continue to promote its mission through psoriasis.org and related educational efforts.

The bottom line: - The six new members deepen NPF’s clinical bench at a time when the organization is trying to shape both care delivery and research for psoriatic disease.